The DOI matches its Crossref record; 227 of the 227 references it cites were found in a registry or an index.
Glutamate system, amyloid β peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology
Open accessAbstract
Alzheimer disease is the most prevalent form of dementia globally and is characterized premortem by a gradual memory loss and deterioration of higher cognitive functions and postmortem by neuritic plaques containing amyloid β peptide and neurofibrillary tangles containing phospho-tau protein. Glutamate is the most abundant neurotransmitter in the brain and is essential to memory formation through processes such as long-term potentiation and so might be pivotal to Alzheimer disease progression. This review discusses how the glutamatergic system is impaired in Alzheimer disease and how interactions of amyloid β and glutamate influence synaptic function, tau phosphorylation and neurodegeneration. Interestingly, glutamate not only influences amyloid β production, but also amyloid β can alter the levels of glutamate at the synapse, indicating that small changes in the concentrations of both molecules could influence Alzheimer disease progression. Finally, we describe how the glutamate receptor antagonist, memantine, has been used in the treatment of individuals with Alzheimer disease and discuss its effectiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–227 of 227
Selective loss of NMDA receptor NR1 subunit isoforms in Alzheimer's disease
Hynd, M. R., Scott, H. L., & Dodd, P. R. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2003.02330.x · Cited by 54
Signaling Mechanisms Underlying Aβ Toxicity: Potential Therapeutic Targets for Alzheimers Disease
Smith, W. W., Gorospe, M., & Kusiak, J. W. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706784111515 · Cited by 52
Solanezumab for Alzheimer's disease
Samadi, H., & Sultzer, D. L. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.578573 · Cited by 48
Dijk, S. N., Francis, P. T., Stratmann, G. C., & Bowen, D. M. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65052165.x · Cited by 48
Bobich, J. A., Zheng, Q., & Campbell, A. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6305 · Cited by 46
Ray, B., Banerjee, P., Greig, N. H., & Lahiri, D. K. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.016 · Cited by 45
Townsend, M., Qu, Y., Gray, A. J., Wu, Z., Seto, T., Hutton, M., Shearman, M. S., & Middleton, R. E. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.163691 · Cited by 44
Ampa/kainate receptor gene expression in normal and alzheimer's disease hippocampus
Pellegrini-Giampietro, D. E., Bennett, M. V. L., & Zukin, R. S. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90058-2 · Cited by 43
Parsons, C. G., & Gilling, K. E. (2007) · Methods in molecular biology · doi:10.1007/978-1-59745-529-9_2 · Cited by 42
Pseudohyperphosphorylation Has Differential Effects on Polymerization and Function of Tau Isoforms
Combs, B., Voss, K., & Gamblin, T. C. (2011) · Biochemistry · doi:10.1021/bi2010569 · Cited by 41
Antibody to β-amyloid protein increases acetylcholine in the hippocampus of 12 month SAMP8 male mice
Farr, S. A., Banks, W. A., Uezu, K., Sano, A., Gaskin, F. S., & Morley, J. E. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00322-9 · Cited by 41
Immunotherapy for Alzheimer’s disease
Solomon, B., & Frenkel, D. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.04.004 · Cited by 37
PARP-1 inhibition to treat cancer, ischemia, inflammation
Graziani, G., Battaini, F., & Zhang, J. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.02.007 · Cited by 36
Morris, J. C. (2002) · Annals of Neurology · doi:10.1002/ana.10135 · Cited by 36
Tsang, S. W. Y., Pomakian, J., Marshall, G. A., Vinters, H. V., Cummings, J. L., Chen, C., Wong, P. T. ‐., & Lai, M. K. P. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.001 · Cited by 35
LEE, R. K. K., JIMENEZ, J., COX, A. J., & Wurtman, R. J. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34443.x · Cited by 34
Adamec, E., Mercken, M. H., Beermann, M. L., Didier, M., & Nixon, R. A. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00166-2 · Cited by 32
Silva, O. A. B. D. C. E., Rebelo, S., Vieira, S. I., Gandy, S., Silva, E. F. D. C. E., & Greengard, P. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05770.x · Cited by 32
The role of STEP in Alzheimer's disease
Kurup, P. K., Zhang, Y., Venkitaramani, D. V., Xu, J., & Lombroso, P. J. (2010) · Channels · doi:10.4161/chan.4.5.12910 · Cited by 29
Long-term potentiation and memory
Morris, R. (2004) · doi:10.1093/oso/9780198530305.003.0007 · Cited by 16
Abe, K., & Misawa, M. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02899-3 · Cited by 15
Becker-Catania, S. G., Nelson, J. K., Olivares, S., Chen, S., & DeVries, G. H. (2011) · ASN NEURO · doi:10.1042/an20100035 · Cited by 15
The mRNA of the NR1 subtype of glutamate receptor in Alzheimer's disease
Panegyres, P. K., Toufexis, K., & Kakulas, B. A. (2002) · Journal of Neural Transmission · doi:10.1007/s702-002-8238-9 · Cited by 14
Paradigm shift in NMDA receptor drug development
Lipton, S. A., & Chen, H.-S. V. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.3.427 · Cited by 14
The role of the N-methyl-D-aspartate receptor in Alzheimer’s disease: Therapeutic potential
Doraiswamy, P. M. (2003) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-003-0019-8 · Cited by 13
Li, M., & Smith, C. P. (1996) · Brain Research Bulletin · doi:10.1016/0361-9230(96)00031-7 · Cited by 10
Parsons, C. G., & Gilling, K. E. (2007) · Humana Press eBooks · doi:10.1007/978-1-60327-090-8_2 · Cited by 5
Cited by
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Rajmohan, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160612 · Cited by 688
Neuroprotective Effects of Quercetin in Alzheimer’s Disease
Khan, H., Ullah, H., Aschner, M., Cheang, W. S., & Akkol, E. K. (2019) · Biomolecules · doi:10.3390/biom10010059 · Cited by 537
Alzheimer’s disease and its treatment by different approaches: A review
Srivastava, S., Ahmad, R., & Khare, S. K. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113320 · Cited by 467
Metadata
- Authors
- Revett, T. J., Baker, G. B., Jhamandas, J., & Kar, S.
- Venue
- Journal of Psychiatry and Neuroscience
- Publisher
- Canadian Science Publishing
- Published
- 2013-01
- Volume
- 38
- Issue
- 1
- Pages
- 6-23
- ISSN
- 1180-4882 (ISSN-L)
- 1488-2434
- OpenAlex
- W2140432027
- Cited by
- 292
- References
- 227
- FWCI
- 13.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.